Compare NBR & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBR | GYRE |
|---|---|---|
| Founded | 1952 | 2002 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 746.4M | 755.7M |
| IPO Year | N/A | N/A |
| Metric | NBR | GYRE |
|---|---|---|
| Price | $68.90 | $7.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $54.13 | $17.00 |
| AVG Volume (30 Days) | ★ 364.8K | 84.8K |
| Earning Date | 02-11-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 14.43 | 0.04 |
| Revenue | ★ $3,116,983,000.00 | $107,265,000.00 |
| Revenue This Year | $9.76 | $11.59 |
| Revenue Next Year | $0.25 | $26.31 |
| P/E Ratio | ★ $4.58 | $209.75 |
| Revenue Growth | ★ 6.52 | 2.13 |
| 52 Week Low | $23.27 | $6.11 |
| 52 Week High | $70.61 | $13.75 |
| Indicator | NBR | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 68.95 | 51.65 |
| Support Level | $63.23 | $7.84 |
| Resistance Level | $70.61 | $8.28 |
| Average True Range (ATR) | 2.72 | 0.32 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 83.38 | 43.70 |
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.